litlas
Log inCreate account

Daniel A. Laheru

Active 2001–2025

105
Papers
33,957
Citations
78
h-index
101
i10-index

Citations

Citations per year for Daniel A. Laheru1986: 1 citations1996: 1 citations2001: 4 citations2002: 13 citations2003: 14 citations2004: 18 citations2005: 25 citations2006: 40 citations2007: 32 citations2008: 41 citations2009: 62 citations2010: 70 citations2011: 109 citations2012: 119 citations2013: 164 citations2014: 271 citations2015: 454 citations2016: 468 citations2017: 520 citations2018: 502 citations2019: 1,551 citations2020: 1,805 citations2021: 1,772 citations2022: 1,303 citations2023: 978 citations2024: 1,448 citations2025: 713 citations2026: 19 citations1987–1995: no citations, so these years are not shown1997–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,397 citing papers, 28.4% of this breakdownChina: 2,123 citing papers, 13.7% of this breakdownGermany: 832 citing papers, 5.4% of this breakdownItaly: 825 citing papers, 5.3% of this breakdownUnited Kingdom: 770 citing papers, 5% of this breakdownJapan: 663 citing papers, 4.3% of this breakdownFrance: 560 citing papers, 3.6% of this breakdownSpain: 460 citing papers, 3% of this breakdownAustralia: 426 citing papers, 2.7% of this breakdownNetherlands: 424 citing papers, 2.7% of this breakdownCanada: 388 citing papers, 2.5% of this breakdownSouth Korea: 359 citing papers, 2.3% of this breakdown
0%28.4%Other 21.1%

Institutions

Fields

  • Medicine59.2%
  • Biochemistry, Genetics and Molecular Biology29.9%
  • Immunology and Microbiology6.9%
  • Engineering1.1%
  • Materials Science1.1%
  • Neuroscience0.4%
  • Other1.4%

Topics

  • Pancreatic and Hepatic Oncology Research12%
  • Cancer Genomics and Diagnostics8.8%
  • Cancer Immunotherapy and Biomarkers6.4%
  • Cancer Cells and Metastasis3.9%
  • Immunotherapy and Immune Responses3.6%
  • Cholangiocarcinoma and Gallbladder Cancer Studies2.1%
  • Other63.2%

Coauthors

All papers

Open in search
  1. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    Authors: Chetan Bettegowda, Mark Sausen, Rebecca Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R. Bartlett, Hao Wang, Brandon Luber, Rhoda M. Alani, Emmanuel S. Antonarakis, Nilofer S. Azad, Alberto Bardelli, Henry Brem, John L. Cameron, Clarence Lee, Leslie A. Fecher, Gary L. Gallia, Peter Gibbs, Dung T. Le, Robert Giuntoli, Michael Goggins, Michael D. Hogarty, Matthias Holdhoff, Seung‐Mo Hong, Yuchen Jiao, Hartmut Juhl, Jaeyeon Kim, Giulia Siravegna, Daniel A. Laheru, Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore‐Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba‐Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian‐Li Wang, Jon Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis A. Díaz - Science Translational Medicine 2014 cited by 5,110

  2. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Authors: Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Malcolm J. Moore, Thomas E. Seay, Sergei Tjulandin, Wen Wee, Mansoor N. Saleh, Marion Harris, Michele Reni, Scot Dowden, Daniel A. Laheru, Nathan Bahary, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, David Goldstein, Eric Van Cutsem, Xinyu Wei, José Iglesias, Markus F. Renschler - New England Journal of Medicine 2013 cited by 6,661

  3. Targeting neoantigens to augment antitumour immunity

    Authors: Mark Yarchoan, Burles A. Johnson, Eric R. Lutz, Daniel A. Laheru, Elizabeth M. Jaffee - Nature reviews. Cancer 2017 cited by 1,032

  4. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

    Authors: Won Jin Ho, Qingfeng Zhu, Jennifer N. Durham, Aleksandra Popović, Stephanie Xavier, James M. Leatherman, Aditya Mohan, Guanglan Mo, Shu Zhang, Nicole Groß, Soren Charmsaz, Dongxia Lin, Derek Quong, Brad Wilt, Ihab R. Kamel, Matthew J. Weiss, Benjamin Philosophe, Richard A. Burkhart, William R. Burns, Chris Shubert, Aslam Ejaz, Jin He, Atul Deshpande, Ludmila Danilova, Genevieve Stein-O’Brien, Elizabeth A. Sugar, Daniel A. Laheru, Robert A. Anders, Elana J. Fertig, Elizabeth M. Jaffee, Mark Yarchoan - Nature Cancer 2021 cited by 346

  5. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

    Authors: Mark Yarchoan, Lee A. Albacker, Alexander C. Hopkins, Meagan Montesion, Karthikeyan Murugesan, Teena Vithayathil, Neeha Zaidi, Nilofer S. Azad, Daniel A. Laheru, Garrett M. Frampton, Elizabeth M. Jaffee - JCI Insight 2019 cited by 538

  6. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

    Authors: Dung T. Le, Andrea Wang‐Gillam, Vincent J. Picozzi, Tim F. Greten, Todd S. Crocenzi, Gregory M. Springett, Michael A. Morse, Herbert J. Zeh, Deirdre Jill Cohen, Robert L. Fine, Beth Onners, Jennifer N. Uram, Daniel A. Laheru, Eric R. Lutz, Sara Solt, Aimee Murphy, Justin Skoble, Ed Lemmens, John Grous, Thomas W. Dubensky, Dirk G. Brockstedt, Elizabeth M. Jaffee - Journal of Clinical Oncology 2015 cited by 600

  7. Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

    Authors: Eric R. Lutz, Annie A. Wu, Elaine Bigelow, Rajni Sharma, Guanglan Mo, Kevin C. Soares, Sara Solt, Alvin Dorman, Anthony Wamwea, Allison Yager, Daniel A. Laheru, Christopher L. Wolfgang, Jiang Wang, Ralph H. Hruban, Robert A. Anders, Elizabeth M. Jaffee, Lei Zheng - Cancer Immunology Research 2014 cited by 544

  8. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

    Authors: Keyu Li, Joseph A. Tandurella, Jessica Gai, Qingfeng Zhu, Su Jin Lim, Dwayne L. Thomas, Tao Xia, Guanglan Mo, Jacob T. Mitchell, Janelle M. Montagne, Melissa R. Lyman, Ludmila Danilova, Jacquelyn W. Zimmerman, Benedict Kinny‐Köster, Tengyi Zhang, Linda Chen, Alex B. Blair, Thatcher Heumann, Rose Parkinson, Jennifer N. Durham, Amol Narang, Robert A. Anders, Christopher L. Wolfgang, Daniel A. Laheru, Jin He, Arsen Osipov, Elizabeth D. Thompson, Hao Wang, Elana J. Fertig, Elizabeth M. Jaffee, Lei Zheng - Cancer Cell 2022 cited by 178

  9. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

    Authors: Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru, E. Gabriela Chiorean, Mark H. O’Hara, Shannon M. Liudahl, Craig Newcomb, Cécile Alanio, Ana Paula Ferreira, Byung Park, Takuya Ohtani, Austin P. Huffman, Sara A. Väyrynen, Andressa Dias Costa, Judith C. Kaiser, Andreanne M. Lacroix, Colleen Redlinger, Martin Stern, Jonathan A. Nowak, E. John Wherry, Martin A. Cheever, Brian M. Wolpin, Emma E. Furth, Elizabeth M. Jaffee, Lisa M. Coussens, Robert H. Vonderheide - Clinical Cancer Research 2021 cited by 180

  10. Metastatic Pancreatic Cancer: ASCO Guideline Update

    Authors: Davendra Sohal, Erin B. Kennedy, Pelin Cinar, Thierry Conroy, Mehmet Sitki Copur, Christopher H. Crane, Ignacio Garrido‐Laguna, Michelle Lau, Tyler Johnson, Smitha Krishnamurthi, Cassadie Moravek, Eileen M. O’Reilly, Philip A. Philip, Shubham Pant, Manish A. Shah, Vaibhav Sahai, Hope E. Uronis, Neeha Zaidi, Daniel A. Laheru - Journal of Clinical Oncology 2020 cited by 289

  11. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

    Authors: Thatcher Heumann, Carol Judkins, Keyu Li, Su Jin Lim, Jessica Hoare, Rose Parkinson, Haihui Cao, Tengyi Zhang, Jessica Gai, Betul Celiker, Qingfeng Zhu, Thomas McPhaul, Jennifer N. Durham, Katrina Purtell, Rachel Klein, Daniel A. Laheru, Ana De Jesus‐Acosta, Dung T. Le, Amol Narang, Robert A. Anders, Richard A. Burkhart, William R. Burns, Kevin C. Soares, Christopher L. Wolfgang, Elizabeth D. Thompson, Elizabeth M. Jaffee, Hao Wang, Jin He, Lei Zheng - Nature Communications 2023 cited by 83

  12. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer

    Authors: Takahiro Tsujikawa, Todd S. Crocenzi, Jennifer N. Durham, Elizabeth A. Sugar, Annie A. Wu, Beth Onners, Julie M. Nauroth, Robert A. Anders, Elana J. Fertig, Daniel A. Laheru, Kim A. Reiss, Robert H. Vonderheide, Andrew H. Ko, Margaret A. Tempero, George A. Fisher, Michael Considine, Ludmila Danilova, Dirk G. Brockstedt, Lisa M. Coussens, Elizabeth M. Jaffee, Dung T. Le - Clinical Cancer Research 2020 cited by 152

  13. Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

    Authors: Dung T. Le, Eric R. Lutz, Jennifer N. Uram, Elizabeth A. Sugar, Beth Onners, Sara Solt, Lei Zheng, Luis A. Díaz, Ross C. Donehower, Elizabeth M. Jaffee, Daniel A. Laheru - Journal of Immunotherapy 2013 cited by 554

  14. A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

    Authors: Annie A. Wu, Katherine M. Bever, Won Jin Ho, Elana J. Fertig, Nan Niu, Lei Zheng, Rose Parkinson, Jennifer N. Durham, Beth Onners, Anna Ferguson, Cara Wilt, Andrew H. Ko, Andrea Wang‐Gillam, Daniel A. Laheru, Robert A. Anders, Elizabeth D. Thompson, Elizabeth A. Sugar, Elizabeth M. Jaffee, Dung T. Le - Clinical Cancer Research 2020 cited by 127

  15. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer

    Authors: Thomas B. Karasic, Mark H. O’Hara, Arturo Loaiza‐Bonilla, Kim A. Reiss, Ursina Teitelbaum, Erkut Borazanci, Ana De Jesus‐Acosta, Colleen Redlinger, Jessica Burrell, Daniel A. Laheru, Daniel D. Von Hoff, Ravi K. Amaravadi, Jeffrey A. Drebin, Peter J. O’Dwyer - JAMA Oncology 2019 cited by 290

  16. Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma

    Authors: Daniel Shu, Won Jin Ho, Luciane T. Kagohara, Alexander A. Girgis, Sarah M. Shin, Ludmila Danilova, Jae W. Lee, Dimitrios N. Sidiropoulos, Sarah Mitchell, Kabeer Munjal, Kathryn L. Howe, Kayla J. Bendinelli, Emma Kartalia, Hanfei Qi, Guanglan Mo, Janelle M. Montagne, James M. Leatherman, Tamara Y. Lopez-Vidal, Qingfeng Zhu, Amanda L. Huff, Xuan Yuan, Alexei Hernandez, Erin M. Coyne, Neeha Zaidi, Daniel J. Zabransky, Elizabeth L. Engle, Aleksandra Ogurtsova, Marina Baretti, Daniel A. Laheru, Jennifer N. Durham, Hao Wang, Joel Sunshine, Robert J. Johnston, Julie S. Deutsch, Janis M. Taube, Robert A. Anders, Elizabeth M. Jaffee, Elana J. Fertig, Mark Yarchoan - Nature Immunology 2024 cited by 89

  17. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

    Authors: Ana De Jesus‐Acosta, Elizabeth A. Sugar, Peter J. O’Dwyer, Ramesh K. Ramanathan, Daniel D. Von Hoff, Zeshaan A. Rasheed, Lei Zheng, Asma Begum, Robert A. Anders, Anirban Maitra, Florencia McAllister, N.V. Rajeshkumar, Shinichi Yabuuchi, Roeland F. de Wilde, Bhavina Batukbhai, İsmet Şahin, Daniel A. Laheru - British Journal of Cancer 2019 cited by 170

  18. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection

    Authors: Georgios Gemenetzis, Vincent P. Groot, Alex B. Blair, Daniel A. Laheru, Lei Zheng, Amol Narang, Elliot K. Fishman, Ralph H. Hruban, Jun Yu, Richard A. Burkhart, John L. Cameron, Matthew J. Weiss, Christopher L. Wolfgang, Jin He - Annals of Surgery 2018 cited by 394

  19. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

    Authors: Kevin C. Soares, Agnieszka A. Rucki, Annie A. Wu, Kelly Olino, Qian Xiao, Yi Chai, Anthony Wamwea, Elaine Bigelow, Eric R. Lutz, Linda Liu, Sheng Yao, Robert A. Anders, Daniel A. Laheru, Christopher L. Wolfgang, Barish H. Edil, Richard D. Schulick, Elizabeth M. Jaffee, Lei Zheng - Journal of Immunotherapy 2014 cited by 394

  20. A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

    Authors: Dung T. Le, Dirk G. Brockstedt, Ran Nir‐Paz, Johannes Hampl, Shruti Mathur, John Nemunaitis, Daniel H. Sterman, Raffit Hassan, Eric R. Lutz, Bentley Moyer, Martin Giedlin, Jana-Lynn Louis, Elizabeth A. Sugar, Alice Pons, Andrea L. Cox, Jordana Levine, Aimee Murphy, Peter B. Illei, Thomas W. Dubensky, Joseph E. Eiden, Elizabeth M. Jaffee, Daniel A. Laheru - Clinical Cancer Research 2011 cited by 368

  21. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma

    Authors: Lei Zheng, Ding Ding, Barish H. Edil, Carol Judkins, Jennifer N. Durham, Dwayne L. Thomas, Katherine M. Bever, Guanglan Mo, Sara Solt, Jessica Hoare, Raka Bhattacharya, Qingfeng Zhu, Arsen Osipov, Beth Onner, Katrina Purtell, Hongyan Cai, Rose Parkinson, Amy Hacker‐Prietz, Joseph M. Herman, Dung T. Le, Nilofer S. Azad, Ana De Jesus‐Acosta, Alex B. Blair, Victoria Kim, Kevin C. Soares, Lindsey Manos, John L. Cameron, Martin A. Makary, Matthew J. Weiss, Richard D. Schulick, Jin He, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Elizabeth A. Sugar, Elizabeth M. Jaffee, Daniel A. Laheru - Clinical Cancer Research 2020 cited by 77

  22. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer

    Authors: Vincent P. Groot, Stacy Mosier, Ammar A. Javed, Jonathan A. Teinor, Georgios Gemenetzis, Ding Ding, Lisa Haley, Jun Yu, Richard A. Burkhart, Alina Hasanain, Marija Debeljak, Hirohiko Kamiyama, Amol Narang, Daniel A. Laheru, Lei Zheng, Ming‐Tseh Lin, Christopher D. Gocke, Elliot K. Fishman, Ralph H. Hruban, Michael Goggins, I. Quintus Molenaar, John L. Cameron, Matthew J. Weiss, Victor E. Velculescu, Jin He, Christopher L. Wolfgang, James R. Eshleman - Clinical Cancer Research 2019 cited by 193

  23. Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

    Authors: Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Daniel A. Laheru, Lon Smith, Tina E. Wood, Ronald L. Korn, Neil Desai, Vuong Trieu, J. L. Mesías Iglesias, Hui Zhang, Patrick Soon‐Shiong, Tao Shi, N.V. Rajeshkumar, Anirban Maitra, Manuel Hidalgo - Journal of Clinical Oncology 2011 cited by 1,045

  24. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

    Authors: Christine A. Iacobuzio–Donahue, Baojin Fu, Shinichi Yachida, Mingde Luo, Hisashi Abe, Clark M. Henderson, F Vilardell, Zheng Wang, Jesse W. Keller, Priya R. Banerjee, Joseph M. Herman, John L. Cameron, Charles J. Yeo, Marc K. Halushka, James R. Eshleman, Marian Raben, Alison P. Klein, Ralph H. Hruban, Manuel Hidalgo, Daniel A. Laheru - Journal of Clinical Oncology 2009 cited by 1,078